Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Aditya Arra, Maximilian Pech, Hang Fu, Holger Lingel, Franziska Braun, Christian Beyer, Myra Spiliopoulou, Barbara M. Bröker, Karen Lampe, Christoph Arens, Katrin Vogel, Mandy Pierau, Monika C. Brunner-Weinzierl
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2021-01-01
Serie:	OncoImmunology
Soggetti:	ctla-4 adults neonates children cd40l multifunctional t-cells s. aureus
Accesso online:	http://dx.doi.org/10.1080/2162402X.2021.1938475
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!